How to Cite this Article: Goodman MJ, Brixner DI. 2013. New therapies for treating Down syndrome require quality of life measurement. Am J Med Genet Part A 161A:639–641
Article first published online: 12 MAR 2013
Copyright © 2013 Wiley Periodicals, Inc.
American Journal of Medical Genetics Part A
Volume 161, Issue 4, pages 639–641, April 2013
How to Cite
Goodman, M. J. and Brixner, D. I. (2013), New therapies for treating Down syndrome require quality of life measurement. Am. J. Med. Genet., 161: 639–641. doi: 10.1002/ajmg.a.35705
The authors have no conflict of interest related to this publication.
- Issue published online: 19 MAR 2013
- Article first published online: 12 MAR 2013
- Manuscript Accepted: 14 SEP 2012
- Manuscript Received: 8 MAY 2012
- Down syndrome;
- quality of life
Down syndrome (DS) is the most common genetic cause of cognitive deficits. Using mouse models and therapies for Alzheimer disease, researchers are exploring therapies that may improve cognitive function in people with DS. These developments shift the health economic paradigm of understanding DS from determining the appropriate screening tool to the effect of therapy on quality of life in those with DS. To date, there are no validated quality of life instruments for DS. Research should begin to develop instruments that can evaluate changes in quality of life in therapeutic trials and beyond. © 2013 Wiley Periodicals, Inc.